KRAS and neoplasm: Regarding preclinical evidence, two previous compounds (ARS-853 and ARS-1620) have demonstrated to reduce cell growth and inhibit downstream signaling to MAPK exclusively in tumor cell lines with KRAS G12C mutations (57, 58, 70).